Skip to main content
letter
. 2022 Jun 19:10.1111/bjh.18315. Online ahead of print. doi: 10.1111/bjh.18315

FIGURE 1.

FIGURE 1

COVID‐19 clinical outcomes of the study population, comparing rituximab and obinutuzumab groups (n = 47).